SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study

Abstract

Patients with MS maintain the capacity to develop humoral immune response against SARS-COV-2, although to a lesser extent when treated with anti-CD20 drugs. Overall, our results are reassuring with respect to the possibility to achieve sufficient immunization with vaccination.